Ansuvimab

Ansuvimab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetZaire ebolavirus
Clinical data
Trade namesEbanga
Other namesAnsuvimab-zykl, mAb114
License data
Routes of
administration
Intravenous
Drug classMonoclonal antibody
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6368H9924N1724O1994S44
Molar mass143950.15 g·mol−1

Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.[1][2]

The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.[1]

Ansuvimab was approved for medical use in the United States in December 2020.[1][2][3] It is on the World Health Organization's List of Essential Medicines.[4]

  1. ^ a b c d "FDA Approves Treatment for Ebola Virus". U.S. Food and Drug Administration. 21 December 2020. Retrieved 23 December 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  2. ^ a b "Ridgeback Biotherapeutics LP Announces the Approval of Ebanga for Ebola" (Press release). Ridgeback Biotherapeutics LP. 22 December 2020. Retrieved 23 December 2020 – via Business Wire.
  3. ^ "Drug Trials Snapshot: Ebanga". U.S. Food and Drug Administration (FDA). 21 December 2020. Retrieved 13 January 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.